Elevate your T-cell manufacturing process

Expanding autologous T-cells for clinical and commercial applications can be challenging when done using traditional methods, due to the high risk of lot-to-lot-variability, contamination and long timespan. Join us for a webinar where Terumo scientific leads will share their current research on the latest perfusion technology for expanding autologous T-cells.

Simplify and de-risk your manufacturing process from process development to commercial.

This webinar was recorded on 25 October 2022.

What will you learn?Who may this interest?Speakers

What will you learn?

  • Streamline the manufacturing process to minimize risks due to open events
  • Take a deep dive into T-cell data on the small and standard bioreactor
  • Review data on minimal seeding requirements for process development
  • Scale from process development to manufacturing on the same platform

Who may this interest?

  • Technical staff, including process development scientists in academic and biotech labs
  • Commercial advanced therapy developers
  • Cell therapy lab managers

Speakers

Mindy Miller Ph.D
Lead Research Scientist
Terumo Blood and Cell Technologies (CO, USA)

Mindy Miller currently serves as the lead research scientist within Terumo Blood and Cell Technologies’ Cell Therapy Technologies team. She holds a doctorate in Immunology from University of Missouri and conducted post-doctoral studies at University of Missouri, as well as National Jewish Health in Denver, CO (all USA).

Mindy’s expertise has focused on the development of immune cells in the context of autoimmunity, allergy and asthma, and pulmonary wound healing. She has authored multiple scientific publications, obtained independent funding and is the recipient of the Young Investigator Award from the American Association of Immunologists.

 

Annie Cunningham
Laboratory Scientist
Terumo Blood and Cell Technologies

Annie is currently a Laboratory Scientist at Terumo Blood and Cell Technologies, leading projects on the Quantum Cell Expansion System and FINIA Fill and Finish System. She has spent most of her career in the biotechnology industry, beginning at Seattle Genetics (WA, USA) where she was part of the BLA submission and FDA approval of ADCETRIS®, an antibody-drug conjugate for CD30+ blood cancer.

She then shifted focus into immunotherapy and contributed to the development of the CAR-T program at Juno Therapeutics, now Bristol Myers Squibb (NY, USA).

After moving to Colorado, Annie continued her research into the human immune system at the University of Colorado (USA) prior to joining the Terumo Blood and Cell Technologies team.

In association with